Bulimia Nervosa Clinical Trial
Official title:
Neurofeedback During Eating: A Novel Mechanistic Treatment for Bulimia Nervosa
NCT number | NCT05614024 |
Other study ID # | GCO 21-2078 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2024 |
Est. completion date | December 2024 |
The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influence inhibitory control and BN symptoms.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion criteria: - Female - Aged 18 to 45 years - Meet diagnostic criteria for bulimia nervosa - Current body mass index greater than or equal to 18.5kg/m2 but under 30kg/m2 - English-speaking Exclusion criteria: - Ongoing medical treatment, major medical condition, or psychiatric disorder that may interfere with study variables or participation - Current psychotherapy focused primarily on eating disorder symptoms - Pregnancy or planned pregnancy, or lactation during the study period - Allergy to ingredients in the standardized meal or in the shake |
Country | Name | City | State |
---|---|---|---|
United States | Center for Computational Psychiatry at the Icahn School of Medicine at Mount Sinai | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Icahn School of Medicine at Mount Sinai |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional near-infrared spectroscopy (fNIRS)-measured neural activation and connectivity | The investigators will evaluate changes in PFC neural activation and connectivity as a function of neurofeedback. | approximately 1 hour | |
Primary | Go/no-go task performance | Participants will complete a go/no-go task 1 week before and 1 week after the neurofeedback session to measure inhibitory control.
Participants behavioral performance on the go/no-go task will be determined by the percentage of incorrect responses made as they are prompted to react to different pictorial stimuli. Participants' percentages of error can range from 0% to 100%. A higher percentage indicates a lower behavioral performance on the task. |
2 weeks | |
Primary | Number of loss-of-control eating and purging episodes | Frequency of loss-of-control eating and purging episodes. Participants will self-report on how often loss-of-control eating and purging episodes occur using electronic daily diaries in the week before and the week after the neurofeedback session. | 2 weeks | |
Primary | Severity of loss-of-control eating scale | Severity of loss-of-control eating. Participants will rate the severity of their feelings of control over eating and purging episodes on a Likert-type scale from 0-10. Higher score indicates greater severity of loss of control. | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04174703 -
Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing
|
N/A | |
Terminated |
NCT04278755 -
Binge Eating & Birth Control
|
Phase 2 | |
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Withdrawn |
NCT00988481 -
Topiramate Augmentation in Bulimia Nervosa Partial Responders
|
Phase 4 | |
Completed |
NCT00184301 -
A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.
|
N/A | |
Completed |
NCT00522769 -
Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents
|
Phase 1/Phase 2 | |
Completed |
NCT00304187 -
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
|
Phase 2 | |
Recruiting |
NCT04409457 -
Self-Control in Bulimia Nervosa
|
N/A | |
Recruiting |
NCT05509257 -
Naltrexone Neuroimaging in Teens With Eating Disorders
|
Early Phase 1 | |
Recruiting |
NCT05937243 -
Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating
|
N/A | |
Recruiting |
NCT05862389 -
Study on the Mechanism of Eating Disorder
|
||
Recruiting |
NCT05728021 -
Smartphone-based Aftercare for Inpatients With Bulimia Nervosa
|
N/A | |
Completed |
NCT03781921 -
The Neural Bases of Emotion Regulation in Bulimia Nervosa
|
||
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Terminated |
NCT04041024 -
Decision-making and Risk-taking in Bulimia
|
N/A | |
Completed |
NCT04265131 -
Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome?
|
N/A | |
Recruiting |
NCT06431854 -
Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program
|
N/A | |
Recruiting |
NCT02960152 -
Periodontal Impact of Eating Disorders (the PERIOED Study)
|
N/A | |
Completed |
NCT00916071 -
Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders
|
N/A | |
Terminated |
NCT00308776 -
Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa
|
N/A |